Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …

The mechanisms by which cells adapt to proteotoxic stress are largely unknown, but are key
to understanding how tumor cells, particularly in vivo, are largely resistant to proteasome …

Long non-coding RNAs (lncRNAs) represent a significant population of the human
transcriptome. Many lncRNAs exhibit cell-and/or tissue/tumor-specific expression, making …

The genetic concept of synthetic lethality has now been validated clinically through the
demonstrated efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of …

The genetic dependencies of human cancers widely vary. Here, we catalog this
heterogeneity and use it to identify functional gene interactions and genotype-dependent …

ABSTRACT RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-
regulated binary on-off switches, which regulate cytoplasmic signaling networks that control …

Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which
mainstream treatments have not changed for decades. To identify additional therapeutic …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …